TSE:GEN

GeneNews Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume473,147 shs
Average Volume1.48 million shs
Market CapitalizationC$25.49 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive GEN News and Ratings via Email

Sign-up to receive the latest news and ratings for GeneNews and its competitors with MarketBeat's FREE daily newsletter.


About GeneNews

GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











GeneNews (TSE:GEN) Frequently Asked Questions

What stocks does MarketBeat like better than GeneNews?

Wall Street analysts have given GeneNews a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but GeneNews wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are GeneNews' key executives?

GeneNews' management team includes the following people:
  • Mr. James R. Howard-Tripp, Exec. Chairman & CEO
  • Ms. Joanna M. Halsey Esq., Gen. Counsel, Chief Compliance Officer & HR Director of IDL
  • Prof. Choong-Chin Liew Ph.D., Co-Founder
  • Mr. Warren Whitehead, Chief Accountant (Age 67)
  • Mr. David Suria, Sr. Scientist

Who are some of GeneNews' key competitors?

What other stocks do shareholders of GeneNews own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GeneNews investors own include StorageVault Canada (SVI), AmerisourceBergen (ABC), American Airlines Group (AAL), Aareal Bank (ARL), (ATE), Broadcom (AVGO), Aspen Technology (AZPN), British American Tobacco (BATS), Cronos Group (CRON) and Edwards Lifesciences (EW).

What is GeneNews' stock symbol?

GeneNews trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GEN."

How do I buy shares of GeneNews?

Shares of GEN and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

How much money does GeneNews make?

GeneNews has a market capitalization of C$0.00 and generates C$234,592.00 in revenue each year.

How many employees does GeneNews have?

GeneNews employs 15 workers across the globe.

What is GeneNews' official website?

The official website for GeneNews is www.genenews.com.

Where are GeneNews' headquarters?

GeneNews is headquartered at 445 Apple Creek Blvd Unit 220, MARKHAM, ON L3R 9X7, Canada.

How can I contact GeneNews?

GeneNews' mailing address is 445 Apple Creek Blvd Unit 220, MARKHAM, ON L3R 9X7, Canada. The company can be reached via phone at +1-905-7392030.


This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.